PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “VARIATION”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 217 records · Page 12Linked to original sources
PubMed1981

[Characterization of genetic EEG-variations with the amplitude-interval-analysis. I. Variations of alpha-activity; flat-EEG; borderline flat EEG, occipital slow beta-waves; monotonous alpha-rhythm (author's transl)].

In 121 healthy adult male probands with different variants of alpha-activity (monotonous alpha-waves; low voltage EEG, borderline low voltage EEG; occipital slow beta-waves) a quantitative description of unipolar leads was carried out using a program for amplitude-interval (time-domain) analysis. Statistically significant differences between means of the examined parameters were discovered between the various EEG variants. No single parameter, however, separates these variants reliably. For such a separation, methods of multivariate statistics will have to be used. Significant differences between right and left hemispheres (primarily lower alpha-activity together with higher beta-activity on the left hemisphere) were found in all EEG types examined except the variant with monotonous alpha-waves.

Alpha Rhythm↗
PubMed1981

Detection of genetic variation with radioactive ligands. IV. X-linked, polymorphic genetic variation of thyroxin-binding globulin (TBG).

A genetically determined, polymorphic electrophoretic variant of thyroxin-binding alpha-globulin (TBG) is found in sera from populations of African and Oceania origin, although not in Caucasians nor Orientals. The TBG polymorphism is inherited in X-linked fashion, based on data from American blacks, and thus provides an X-chromosome marker with a relatively high gene frequency in this ethnic group (frequency of the slow allele, TBGs, is 11%). This slow variant should prove valuable in expanding the map of the X chromosome and in linkage studies. An additional family exhibiting X-linked TBG deficiency is also described.

Chromosome Mapping↗
PubMed1976

[Individual variations in the frequency of chromosome aberrations following exposure to chemical mutagens. II. Interindividual variation in the frequency of chromosome aberrations in the presence of different mutagen concentrations].

The object of this investigation was the distribution of human periferal blood cultured obtained from different donors with respect to their sensitivity to different concentrations of thiophosphamide (10, 20 and 30 mcg/ml for 1 hour). Two test characteristics were studied, "the proportion of aberrant metaphases" and "the number of chromosome breaks per 100 cells". It is shown that the distribution of individuals does not depend on the mutagen concentration, being normal in all the series of experiments. The same results were obtained when two different statistical methods were used, viz. the method of four moments and the chi-square test. Since the former method is less labour-consuming, the authors recommend it for fitting the normal distribution in cytogenetic investigations. The variances of the test-characteristics studies ("percent aberrant metaphases" and "total number of breaks per 100 cells") increased with the increase of the mean values. Therefore, before the analysis of variance and the regression analysis the cytogenetic data should be preliminary transformed for the purpose of stabilization of variances.

Chromosome Aberrations↗
PubMed1998

Genetic variation of HIV type 1: relevance of interclade variation to vaccine development.

Accumulating data in human immunodeficiency virus (HIV)-infected individuals support the hypothesis that in primary human immunodeficiency virus type 1 (HIV-1) isolates of different clades and phenotype (syncytium inducing [SI] and nonsyncytium inducing [NSI]) common antigenic structures must exist that can stimulate the immune response to produce a broad spectrum (cross-clade and cross SI and NSI) neutralization response. Certain vaccination regimens in chimpanzees and human volunteers with clade B SI type HIV-1 derived candidate vaccines induce neutralizing antibodies against intraclade B SI type primary HIV-1 isolates, but not against intraclade B NSI type of viruses. To be effective against the full antigenic spectrum of primary HIV-1 isolates (cross-clade--SI and NSI) candidate vaccines should contain immunogens of primary isolates representative of the whole antigenic spectrum of HIV-1. There is an urgent need to identify these immunogens and to improve their immunogenicity. As long as we have not yet characterized these cross-HIV-1 spectrum conserved immunogens, candidate vaccines against the more prevalent clades C, A, and E should be developed for evaluation in developing countries. In support of the follow-up and evaluation of the hopefully increasing number of phase 1, 2, and 3 HIV-1 vaccine trials in humans, it is considered a high priority to develop a high throughput neutralization assay, to further expand the use of a limited number of key primary HIV-1 isolates as a surrogate for neutralization of the entire HIV-1 antigenic spectrum (cross-clade--SI and NSI), to develop high throughput subtyping as well as a rapid system to monitor the immunogenic relatedness of different HIV-1 clades.

AIDS Vaccines↗
PubMed1989

Absence of tobramycin pharmacokinetic and creatinine clearance variation during the menstrual cycle: implied absence of variation in glomerular filtration rate.

During the menstrual cycle, a 20% increase in creatinine clearance (CL(CR] has previously been reported between the menstrual (phase 1) and late luteal (phase 4) phases. Tobramycin pharmacokinetics and CL(CR) were studied in eight healthy women with documented, regular, ovulatory menses. During the first and fourth phases of the menstrual cycle (as determined by urinary luteinizing hormone peak and basal body temperature shift), subjects received tobramycin by intravenous bolus. Tobramycin half-life, total body clearance, and volume of distribution were not significantly different between the two study phases. No significant change in total urinary creatinine excretion or CL(CR) was seen between phases. Total 24 hour urinary recovery of tobramycin was 98-99.7%. We conclude that no significant changes in renal function, as evaluated by tobramycin pharmacokinetics and CL(CR), occur between these hormonally different phases of the menstrual cycle, and that urinary recovery of a single dose of tobramycin is nearly complete within 24 hours in premenopausal women with normal renal function.

Adult↗
PubMed1987

A theophylline dosage regimen which reduces round-the-clock variations in plasma concentrations resulting from diurnal pharmacokinetic variation.

Slower drug absorption at night can leave residual drug from an evening dose of a sustained-release product remaining to be absorbed at the time of the next morning's dose, thereby giving higher plasma concentrations of the drug during the day than the night. When a capsule product releasing theophylline over 12 h after a morning dose was given repetitively at 8 a.m. and 8 p.m. for 4 days, daytime plasma concentrations from 4 h to 8 h after the dose were about 40% greater than corresponding night-time concentrations, and the mean steady-state concentration during the night-time interval was only 81% of that during the daytime interval. Altering the regimen to one capsule at 12 noon and one at 10 p.m. eliminated all significant differences between a.m. and corresponding p.m. plasma concentrations of theophylline and between the mean steady-state concentrations for each of the interdose intervals within a day.

Adult↗